Anti-HER2 therapy in elderly breast cancer patients

Rev Recent Clin Trials. 2014;9(4):263-6. doi: 10.2174/1574887109666141127102035.

Abstract

Targeting anti-HER-2 therapy, trastuzumab, Lapatinib, T-DM1, and Pertuzumab is a standard therapy for HER-2-overexpressing breast cancer. But there are less data available related to anti-HER-2 therapy in elderly patients because they have been consistently underrepresented in clinical trials. Anti- HER-2 therapy among an elderly population was reviewed including approaches for making treatment effective.

Publication types

  • Review

MeSH terms

  • Aged
  • Antineoplastic Agents / therapeutic use
  • Breast Neoplasms* / drug therapy
  • Breast Neoplasms* / genetics
  • Breast Neoplasms* / metabolism
  • DNA, Neoplasm / genetics
  • Female
  • Gene Expression Regulation, Neoplastic / drug effects
  • Humans
  • Receptor, ErbB-2 / antagonists & inhibitors*
  • Receptor, ErbB-2 / biosynthesis
  • Receptor, ErbB-2 / genetics
  • Trastuzumab / therapeutic use*
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • DNA, Neoplasm
  • ERBB2 protein, human
  • Receptor, ErbB-2
  • Trastuzumab